bendamustine hydrochloride has been researched along with abt-199 in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 11 (55.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, HJ; Beckmann, L; Brinkmann, K; Fandrey, J; Frenzel, LP; Hallek, M; Huelsemann, MF; Kashkar, H; Otto, T; Pallasch, CP; Patz, M; Reinhardt, HC; Theurich, S; von Bergwelt-Baildon, M; Wendtner, CM; Zahedi, RP | 1 |
| Balakrishnan, K; Cervantes-Gomez, F; Gandhi, V; Keating, MJ; Lamothe, B; Wierda, WG; Woyach, JA | 1 |
| Cramer, P; Eichhorst, B; Hallek, M; Reinhardt, HC | 1 |
| Bahlo, J; Böttcher, S; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Hallek, M; Kreuzer, KA; Langerbeins, P; Stilgenbauer, S; von Tresckow, J; Wendtner, CM | 1 |
| Assouline, S; Boyer, M; Cartron, G; D'Rozario, J; De la Serna, J; Eichhorst, B; Gerecitano, J; Hillmen, P; Humerickhouse, R; Humphrey, K; Jaeger, U; Kater, AP; Kipps, TJ; Li, Y; Mobasher, M; Montillo, M; Owen, C; Punnoose, EA; Robak, T; Seymour, JF | 1 |
| Agarwal, S; Cordero, J; de Vos, S; Dunbar, M; Enschede, SH; Flowers, CR; Fowler, N; Kozloff, M; Nastoupil, LJ; Nolan, C; Petrich, AM; Reid, E; Ross, JA; Salem, AH; Swinnen, LJ; Verdugo, M; Wang, D; Zhou, L | 1 |
| Armitage, JO; Kallam, A | 1 |
| Al-Sawaf, O; Bahlo, J; Böttcher, S; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer von Weikersthal, L; Fischer, K; Hallek, M; Hebart, H; Kneba, M; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Seiler, T; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM | 1 |
| Boyer, M; Eichhorst, B; Hillmen, P; Humphrey, K; Jiang, Y; Kater, AP; Kipps, TJ; Langerak, AW; Mobasher, M; Owen, C; Punnoose, EA; Seymour, JF; Verdugo, M; Wang, J; Wu, J | 1 |
| Arthur, C; Crump, M; Fleury, I; Flinn, IW; Gritti, G; Hiddemann, W; Humphrey, K; Kornacker, M; Le Dû, K; Mobasher, M; Petrich, A; Pro, B; Punnoose, EA; Rusconi, C; Samineni, D; Sinha, A; Spielewoy, N; Szafer-Glusman, E; Topp, MS; Yuen, SLS; Zinzani, PL | 1 |
| Cartron, G; Eichhorst, B; Giever, T; Hallek, M; Huang, H; Humphrey, K; Jiang, Y; Kozloff, MF; Lozanski, G; Mobasher, M; Morschhauser, F; Pignataro, DS; Salles, G; Schary, W; Stilgenbauer, S; Wendtner, CM | 1 |
| Fowler, N | 1 |
| Al-Sawaf, O; Cramer, P; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Giza, A; Hallek, M; Kneba, M; Langerbeins, P; Pelzer, BW; Robrecht, S; Schneider, C; Stilgenbauer, S; Tausch, E; von Tresckow, J; Wendtner, CM | 1 |
| Abdeldayem, A; Aittokallio, T; Bhatti, MN; Bukhari, S; de Araujo, ED; Gawel, JM; Geletu, M; Gunning, PT; Hassan, MM; Herling, M; Ianevski, A; Israelian, J; Krämer, OH; Manaswiyoungkul, P; Moriggl, R; Mustjoki, S; Nawar, N; Neubauer, HA; Olaoye, OO; Radu, TB; Raouf, YS; Sedighi, A; Shouksmith, AE; Sorger, H; Timonen, S; Toutah, K; von Jan, J | 1 |
| Cohen, JB; Romancik, JT | 1 |
| Cahill, KE; Smith, SM | 1 |
| Assouline, S; Boyer, M; Cartron, G; Chyla, B; D'Rozario, J; de la Serna, J; Eichhorst, BF; Jaeger, U; Jiang, Y; Kater, AP; Kipps, TJ; Lamanna, N; Lefebure, M; Lu, T; Mellink, C; Montillo, M; Owen, CJ; Panchal, A; Robak, T; Seymour, JF; Wu, JQ | 1 |
| Al-Sawaf, O; Böttcher, S; Brüggemann, M; Cramer, P; Dreger, P; Eichhorst, B; Fink, AM; Fischer, K; Fürstenau, M; Giza, A; Hallek, M; Kneba, M; Kreuzer, KA; Langerbeins, P; Ritgen, M; Robrecht, S; Schetelig, J; Schilhabel, A; Schneider, C; Stilgenbauer, S; Tausch, E; Zhang, C | 1 |
| De la Serna-Torroba, J; Escudero-Vilaplana, V; Hernández-Rivas, JÁ; Moreno-Martínez, E; Sánchez-Cuervo, M; Sánchez-Hernández, R | 1 |
| Bahlo, J; Baumann, M; Brüggemann, M; Christiansen, I; da Cunha-Bang, C; De Silva, N; Eichhorst, B; Enggaard, L; Fink, AM; Fischer, K; Frederiksen, H; Fürstenau, M; Gaska, T; Geisler, C; Goede, J; Gregor, M; Hallek, M; Hebart, H; Hoogendoorn, M; Illmer, T; Jäger, U; Janssens, A; Juliusson, G; Kater, AP; Koene, H; Kreuzer, KA; Levin, MD; Leys, MBL; Lindström, V; Lotfi, K; Niemann, CU; Nösslinger, T; Poulsen, CB; Regelink, JC; Ritgen, M; Robrecht, S; Schneider, C; Schöttker, B; Simon, F; Staber, PB; Stilgenbauer, S; Tadmor, T; Tausch, E; Thornton, P; van der Klift, M; van Oers, M; von Tresckow, J; Wendtner, CM; Widmer, A; Zhang, C | 1 |
3 review(s) available for bendamustine hydrochloride and abt-199
| Article | Year |
|---|---|
Current strategies to create tailored and risk-adapted therapies for CLL patients.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase II as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Precision Medicine; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Risk Factors; Sulfonamides | 2016 |
Sequencing of Novel Therapies for Mantle Cell Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Glucocorticoids; Humans; Immunotherapy, Adoptive; Induction Chemotherapy; Lenalidomide; Lymphoma, Mantle-Cell; Proteasome Inhibitors; Protein Kinase Inhibitors; Receptors, Chimeric Antigen; Rituximab; Stem Cell Transplantation; Sulfonamides; Transplantation, Autologous; Transplantation, Homologous | 2021 |
Follicular Lymphoma: a Focus on Current and Emerging Therapies
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Doxorubicin; Genetic Testing; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy, Adoptive; Lenalidomide; Lymphoma, Follicular; Maintenance Chemotherapy; Morpholines; Neoplasm Recurrence, Local; Phosphoinositide-3 Kinase Inhibitors; Prednisone; Pyridones; Rituximab; Sulfonamides; Vincristine | 2022 |
11 trial(s) available for bendamustine hydrochloride and abt-199
| Article | Year |
|---|---|
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Marrow; Bridged Bicyclo Compounds, Heterocyclic; Humans; Induction Chemotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm, Residual; Purines; Quinazolinones; Sulfonamides; Treatment Outcome | 2018 |
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Recurrence; Rituximab; Sulfonamides; Tumor Lysis Syndrome; Young Adult | 2018 |
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Rituximab; Salvage Therapy; Sulfonamides | 2018 |
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Sulfonamides; Time Factors; Treatment Outcome | 2018 |
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Progression-Free Survival; Recurrence; Rituximab; Sulfonamides; Time Factors | 2019 |
Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Recurrence; Rituximab; Sulfonamides | 2020 |
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Sulfonamides | 2021 |
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Female; Gene Deletion; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Piperidines; Progression-Free Survival; Prospective Studies; Sulfonamides; Tumor Suppressor Protein p53 | 2021 |
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Recurrence; Rituximab; Sulfonamides | 2022 |
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cytoreduction Surgical Procedures; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Sulfonamides | 2022 |
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Rituximab | 2023 |
6 other study(ies) available for bendamustine hydrochloride and abt-199
| Article | Year |
|---|---|
Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; B-Lymphocytes; bcl-X Protein; Bendamustine Hydrochloride; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; CD40 Ligand; Cell Hypoxia; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Nitrogen Mustard Compounds; Nitrophenols; Oxygen; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sulfonamides; Vidarabine | 2015 |
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Cell Activating Factor; bcl-X Protein; Bendamustine Hydrochloride; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Female; Gene Expression Regulation, Leukemic; Humans; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplastic Cells, Circulating; Nitrophenols; Piperazines; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyrimidines; Sulfonamides | 2015 |
Venetoclax in chronic lymphocytic leukaemia: a possible cure?
Topics: Antibodies, Monoclonal, Humanized; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Sulfonamides | 2018 |
BCL-2 inhibition in follicular lymphoma: can we tip the scales?
Topics: Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Humans; Lymphoma, Follicular; Proto-Oncogene Proteins c-bcl-2; Rituximab; Sulfonamides | 2020 |
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Synergism; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Prolymphocytic, T-Cell; Male; Mice; Molecular Docking Simulation; Molecular Structure; para-Aminobenzoates; Pyrrolidines; Structure-Activity Relationship; Sulfonamides | 2021 |
Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bridged Bicyclo Compounds, Heterocyclic; Chlorambucil; Cost-Benefit Analysis; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Quality of Life; Rituximab; Spain; Sulfonamides | 2022 |